Free Membership
Newsletter
Help
Subscribe
Sign In
Search
March 8, 2021
All times are Vienna time
Search
Subscribe
Sign In
Countries:
Africa »
Algeria Angola Benin Botswana Burundi Côte d'Ivoire Ghana Guinea Kenya Lesotho Liberia Libya Mali Mauritius Morocco Mozambique Namibia Niger Nigeria Rwanda South Africa Sudan Tanzania The Congo Togo Tunisia Uganda Zambia Zimbabwe
Asia-Pacific »
Afghanistan Australia Bangladesh Cambodia China Hong Kong SAR India Indonesia Japan Laos Malaysia Mongolia Nepal New Zealand North Korea (DPRK) Pakistan Philippines Singapore South Korea Sri Lanka Taiwan Thailand Vietnam
Central- & Eastern Europe »
Albania Bosnia & Herzegovina Bulgaria Croatia Czech Rep. Estonia Georgia Hungary Kosovo Latvia Lithuania North Macedonia Montenegro Poland Romania Serbia Slovakia Slovenia Ukraine Western Balkans
Middle East »
Egypt Iran Iraq Israel Jordan Kuwait Lebanon Oman Palestinian Territories Qatar Saudi Arabia Syria Turkey United Arab Emirates Yemen
Russia & CIS »
Russia Armenia Azerbaijan Belarus Kazakhstan Kyrgyzstan Moldova Turkmenistan Uzbekistan
The Americas »
Argentina Bolivia Brazil Canada Central America Chile Colombia Ecuador Mexico Paraguay Peru The Caribbean Uruguay Venezuela
United States
Western Europe »
Belgium Cyprus Denmark Finland France Germany Greece Iceland Ireland Italy Liechtenstein Luxembourg Malta Monaco Norway Portugal Scotland Spain Sweden Switzerland The Netherlands United Kingdom Vatican City
Business:
Economy
Economic Policies
Investing in Austria
Securities
Earnings
Foreign Trade
Deals
Legal Issues
More Business & Economics+
Politics:
Domestic
Brussels
International
Diplomacy
Companies:
Professional Services »
Banks Financial Services Real Estate Insurance Other Services
Energy »
Oil & Gas Utilities Renewables Mining
Industrials »
Construction Automotive Industrial Goods Basic Resources Chemicals Other Industrials
Transport »
Airlines & Airports Shipping Rail Road
Retail & Consumer
Health Care
Technology
Telecoms
Media
Tourism
Other
Organizations:
Diplomatic Missions
International Organizations
Other
People:
Executives
Politicians
Diplomats
Entrepreneurs
Other
Lifestyle & Travel:
Culture
Travel
Personal Real Estate
Health
Food & Drink
Luxury Goods
More+
More+:
Events
Photo Galleries
Videos
Classifieds
Work & Careers
More+
Home
Countries
Business
Politics
Diplomacy
Companies
Organizations
People
Lifestyle & Travel
More+
Africa
Algeria
Angola
Benin
Botswana
Burundi
Côte d'Ivoire
Ghana
Guinea
Kenya
Lesotho
Liberia
Libya
Mali
Mauritius
Morocco
Mozambique
Namibia
Niger
Nigeria
Rwanda
South Africa
Sudan
Tanzania
The Congo
Togo
Tunisia
Uganda
Zambia
Zimbabwe
Asia-Pacific
Afghanistan
Australia
Bangladesh
Cambodia
China
Hong Kong SAR
India
Indonesia
Japan
Laos
Malaysia
Mongolia
Nepal
New Zealand
North Korea (DPRK)
Pakistan
Philippines
Singapore
South Korea
Sri Lanka
Taiwan
Thailand
Vietnam
Central- & Eastern Europe
Albania
Bosnia & Herzegovina
Bulgaria
Croatia
Czech Rep.
Estonia
Georgia
Hungary
Kosovo
Latvia
Lithuania
North Macedonia
Montenegro
Poland
Romania
Serbia
Slovakia
Slovenia
Ukraine
Western Balkans
Middle East
Egypt
Iran
Iraq
Israel
Jordan
Kuwait
Lebanon
Oman
Palestinian Territories
Qatar
Saudi Arabia
Syria
Turkey
United Arab Emirates
Yemen
Russia & CIS
Russia
Armenia
Azerbaijan
Belarus
Kazakhstan
Kyrgyzstan
Moldova
Turkmenistan
Uzbekistan
The Americas
Argentina
Bolivia
Brazil
Canada
Central America
Chile
Colombia
Ecuador
Mexico
Paraguay
Peru
The Caribbean
Uruguay
Venezuela
United States
Western Europe
Belgium
Cyprus
Denmark
Finland
France
Germany
Greece
Iceland
Ireland
Italy
Liechtenstein
Luxembourg
Malta
Monaco
Norway
Portugal
Scotland
Spain
Sweden
Switzerland
The Netherlands
United Kingdom
Vatican City
Economy
Economic Policies
Investing in Austria
Securities
Earnings
Foreign Trade
Deals
Legal Issues
More Business & Economics+
Domestic
Brussels
International
Professional Services
Banks
Financial Services
Real Estate
Insurance
Other Services
Energy
Oil & Gas
Utilities
Renewables
Mining
Industrials
Construction
Automotive
Industrial Goods
Basic Resources
Chemicals
Other Industrials
Transport
Airlines & Airports
Shipping
Rail
Road
Retail & Consumer
Health Care
Technology
Telecoms
Media
Tourism
Other
Diplomatic Missions
International Organizations
Other
Executives
Politicians
Diplomats
Entrepreneurs
Other
Culture
Travel
Personal Real Estate
Health
Food & Drink
Luxury Goods
More+
Events
Photo Galleries
Videos
Classifieds
Work & Careers
More+
Latest News
Coronavirus in Austria
Embassies
Expats
USA in Vienna
UK in Vienna
Russia in Vienna
France in Vienna
UN Vienna
OSCE
IAEA
OPEC
Sponsored Content
Tweet
Share

EMA Approves Covid-19 Vaccine

Lifestyle & Travel › Health ♦ Published: December 21, 2020; 19:50 ♦ (Vindobona)
Sponsored Content

The European Medicines Agency (EMA) recommended the approval of a Covid-19 vaccine developed by BioNTech and Pfizer. Ultimately, the European Commission granted approval and the first vaccine will be used on December 27. Further Covid-19 vaccinations are awaiting approvals in the upcoming weeks.

The EU approved the first Covid-19 vaccine developed by BioNTech and Pfizer. / Picture: © Flickr / Tim Reckmann (CC BY 2.0)

The European Medicines Agency (EMA) recommended granting conditional marketing authorization for the vaccine "Comirnaty" developed by BioNTech and Pfizer to prevent Covid-19 in people aged 16 and older.

The EMA's scientific opinion paves the way for the first marketing authorization of a Covid-19 vaccine in the EU by the European Commission, with all associated safeguards, controls and obligations.

EMA has just recommended granting a conditional marketing authorisation for the #COVID19vaccine developed by BioNTech/ Pfizer, to prevent #COVID19 in people from 16 years of age.

Read our press release: https://t.co/qOyMcYLI4y pic.twitter.com/4c5ujZKQ6b

Sponsored Content
— EU Medicines Agency (@EMA_News) December 21, 2020

Austria's Health Minister Rudolf Anschober:

"This is very good news! A total of 1 million doses will be delivered by BioNTech in the first quarter, of which about 230,000 will be delivered in the first four weeks. We will then start vaccinating the elderly and nursing homes with these doses."

He added:

"After that, we still expect the market approval of Moderna at the beginning of January, and then a delivery of this vaccine of 200,000 doses in the first quarter. And after that, market approval of the vaccine from AstraZeneca in February. Of that, 1.2 million doses will be delivered in the first quarter."

The EMA Committee for Medicinal Products for Human Use (CHMP) has completed its rigorous evaluation of Comirnaty and concluded that sufficient robust data on the quality, safety and efficacy of the vaccine are now available to recommend a formal conditional marketing authorization.

This should provide a controlled and robust framework to support EU-wide vaccination campaigns and protect EU citizens, according to Anschober.

"Due to the excellent cooperation of all experts, it was possible to issue a positive opinion for the first mRNA vaccine Comirnaty in the EU this year. Even the news from the UK that there is a new viral variant will not diminish the success of the vaccine, because the immune response that the vaccine elicits is directed against several features of the virus, individual mutations should therefore not have a dramatic effect," said Dr. Christa Wirthumer-Hoche, head of the Medical Market Supervisory business area in Austria in an initial reaction to the positive news from Amsterdam.

A very large clinical trial has shown that the vaccine effectively prevents Covid-19 in people 16 years and older.

The trial involved a total of about 44,000 people. Half received the vaccine and the other half received a placebo. People did not know whether they received the vaccine or the placebo´.

Efficacy was calculated in more than 36,000 people 16 years and older (including people 75 years and older) who had no evidence of previous infection.

Sponsored Content
Sponsored Content

The study showed a 95% reduction in the number of symptomatic Covid-19 cases among people who received the vaccine (8 of 18,198 cases had Covid-19 symptoms) compared with people who received a sham injection (162 of 18,325 cases had Covid-19 symptoms). This means that the vaccine showed 95% efficacy in the clinical trial.

The study also showed about 95% efficacy among participants at risk for severe Covid-19 disease, including those with asthma, chronic lung disease, diabetes, high blood pressure, or a high body mass index. High efficacy was also maintained across gender, race, and ethnic groups.

Copyright © Vindobona. You may share using our article tools. Please don't cut articles from Vindobona and redistribute by email or post to the web.
Sponsored Content
Fast News Search
Related News
EUR 2.4 Million for Covid-19 Vaccine in Developing Countries (December 17, 2020)
Von der Leyen Hopes for Joint Start of Covid-19 Vaccinations (December 16, 2020)
European Council: Kurz Hopes for Rapid Approval of Vaccine (December 10, 2020)
Read More
Vaccines, Rudolf Anschober, Pfizer Corporation Austria, EMA European Medicines Agency, COVID-19, Coronavirus, Biontech, 2019-nCov
Featured
See latest Vindobona Newsletter
Sponsored Content
Sign up now for full site access and to read a limited amount of free premium articles per month:
Sign Up
×
Sponsored Content
Sponsored Content
©1995-2021 Vindobona
Contact
Help
Imprint
Press
Careers
Partners
Terms & Conditions
Site Security
Privacy
Sitemap
Advertise
About Us